Silencing BAG1 in breast cancer cells increases resistance to tamoxifen and reduces apoptosis by activating the PI3K/Akt/mTOR signaling pathway (34), and the overexpression of ATG16L2 is related to poor prognosis in epithelial cancer (35). Here, BAG1 is linked to breast carcinoma.